Mesoblast faces fresh class action investigation over stem cell therapy claims

Class Actions 2022-02-23 3:56 pm By Bianca Hrovat | Sydney

Please login to bookmark

A second class action investigation against regenerative medicine company Mesoblast is underway, this one looking at claim it misled shareholders about the potential application of a developmental stem cell product to treat terminally-ill children.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au